stockrowCorcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.
- Revenue
- +64.0%
- EPS
- +525.8%
- Free cash flow
- +161.0%
Quarter to September 2026, against a year earlier
Follow CORT
Alert me
Corcept Therapeutics Incorporated (CORT) EBITDA
Corcept Therapeutics Incorporated's EBITDA for fiscal 2025 was $41.6M, down 67.3% from $127.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was $108.8M. Over the past ten years it has ranged from −$3.3M (fiscal 2015) to $133.0M (fiscal 2021); the current reading is higher than 27% of that period. Corcept Therapeutics Incorporated ranks 25th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $41.6M | (67.35%) |
| FY2024 | $127.3M | 26.70% |
| FY2023 | $100.5M | (14.43%) |
| FY2022 | $117.5M | (11.71%) |
| FY2021 | $133.0M | 1.99% |
| FY2020 | $130.4M | 14.64% |
| FY2019 | $113.8M | 29.28% |
| FY2018 | $88.0M | 66.14% |
| FY2017 | $53.0M | 414.97% |
| FY2016 | $10.3M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $115.8M | 174.53% |
| Jun 2026 | $42.2M | — |
| Mar 2026 | −$49.0M | — |
| Dec 2025 | −$134.0K | — |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $234.3M |
| CORT Corcept Therapeutics Incorporated | $108.8M |
| PTGX Protagonist Therapeutics, Inc. compare | $56.4M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$145.8M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$204.6M |
| SYRE Spyre Therapeutics, Inc. compare | −$250.2M |
| ABVX Abivax SA Sponsored ADR compare | −$338.0M |
| PRAX Praxis Precision Medicines, Inc. compare | −$380.8M |
| CYTK Cytokinetics, Incorporated compare | −$694.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on CORT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement